Could Investing in Moderna's Stock Double Your Money?
Key PointsIntismeran is a promising cancer vaccine that has been highly effective when paired with Keytruda.
Moderna's stock has surged over 650% year-to-date, fueled by anticipation surrounding its cancer vaccine, intismeran. However, investors may wonder if now is a good time to invest in Moderna in hopes of doubling their money. Recent clinical trials have shown intismeran to be effective in reducing the risk of death or recurrence in melanoma patients, with Merck evaluating its potential use for other cancers.
If successful, this could significantly boost Moderna's future revenue. Despite the stock's impressive performance this year, it's still down about 36% over the past five years. Still, with intismeran awaiting approval, there's optimism that it could revolutionize Moderna's business. For Moderna's stock to double, it would need to reach a valuation of around $180 billion, a goal that may take some time to achieve.
While Moderna shows immense potential, investors with a lower risk tolerance might want to consider other options.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
